• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Costs of Stroke and Incidence of First Diagnosis of Atrial Fibrillation at Time of Stroke. Neurology Ward Hospital Poznań, Poland 2018.中风的成本以及中风时首次诊断心房颤动的发生率。波兰波兹南神经病学病房医院,2018年。
Healthcare (Basel). 2021 Aug 5;9(8):999. doi: 10.3390/healthcare9080999.
2
Costs of inpatient care of depression in 2014 in Polish (Poznan) and German (Kiel) hospital.2014 年波兰(波兹南)和德国(基尔)医院住院治疗抑郁症的费用。
Int J Psychiatry Clin Pract. 2019 Nov;23(4):258-264. doi: 10.1080/13651501.2019.1611863. Epub 2019 May 20.
3
The economic burden of inpatient care of depression in Poznan (Poland) and Kiel (Germany) in 2016.2016 年波兰波兹南和德国基尔因住院治疗抑郁症带来的经济负担。
PLoS One. 2018 Jun 14;13(6):e0198890. doi: 10.1371/journal.pone.0198890. eCollection 2018.
4
The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention
.新型口服抗凝药在预防心房颤动相关卒中方面的成本节约
Int J Clin Pharmacol Ther. 2017 Mar;55(3):220-230. doi: 10.5414/CP202651.
5
Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry.波兰及其他欧洲国家心房颤动患者的卒中预防:来自GARFIELD-AF注册研究的见解
Kardiol Pol. 2016;74(4):362-71. doi: 10.5603/KP.a2015.0173. Epub 2015 Sep 14.
6
Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.在法国,被诊断为心房颤动的患者中风和出血的发生率和成本。
J Stroke Cerebrovasc Dis. 2014 Feb;23(2):e73-83. doi: 10.1016/j.jstrokecerebrovasdis.2013.08.022. Epub 2013 Oct 8.
7
Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study.心房颤动患者发生重大颅内、胃肠道及其他出血事件的成本——一项全国性队列研究
BMC Health Serv Res. 2017 Jun 12;17(1):398. doi: 10.1186/s12913-017-2331-z.
8
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.心房颤动卒中预防的变化格局:GLORIA-AF 注册研究 2 期结果。
J Am Coll Cardiol. 2017 Feb 21;69(7):777-785. doi: 10.1016/j.jacc.2016.11.061.
9
New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.新型口服抗凝药预防心房颤动血栓栓塞并发症的单中心经验
Kardiol Pol. 2015;73(2):85-93. doi: 10.5603/KP.a2014.0168. Epub 2014 Sep 2.
10
Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.处方正确吗?非瓣膜性心房颤动患者非维生素K拮抗剂抗凝剂(NOAC)处方的回顾。心房颤动安全处方及非维生素K口服抗凝剂在预防卒中中的评估(SAFE-NOACS)组。
Ir J Med Sci. 2019 Feb;188(1):101-108. doi: 10.1007/s11845-018-1837-7. Epub 2018 Jun 2.

引用本文的文献

1
Design and Evaluation of ACAFiB-APP, a clinical decision support system for anticoagulant considerations in patients with atrial fibrillation.ACAFiB-APP的设计与评估,一种用于心房颤动患者抗凝治疗考量的临床决策支持系统。
BMC Cardiovasc Disord. 2025 Mar 8;25(1):166. doi: 10.1186/s12872-025-04615-w.
2
Patient satisfaction survey of the "Healthy Heart" pharmaceutical care service - evaluation of pharmacy labelling with pharmaceutical pictograms.“健康之心”药学服务患者满意度调查-评估带有药学图形标志的药品标签。
BMC Health Serv Res. 2023 Sep 7;23(1):962. doi: 10.1186/s12913-023-09986-4.
3
Prevalence of Cardio-Embolic Brain Complications in Permanent and Paroxysmal Atrial Fibrillation Patients.持续性和阵发性心房颤动患者中心源性脑栓塞并发症的患病率
Healthcare (Basel). 2023 Jan 6;11(2):175. doi: 10.3390/healthcare11020175.

本文引用的文献

1
Sex differences in direct healthcare costs following stroke: a population-based cohort study.
BMC Health Serv Res. 2021 Jun 29;21(1):619. doi: 10.1186/s12913-021-06669-w.
2
Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015-2017 Years.波兰心血管疾病的经济成本:2015 - 2017年估算
Front Pharmacol. 2020 Sep 8;11:1231. doi: 10.3389/fphar.2020.01231. eCollection 2020.
3
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动诊断和管理指南:欧洲心脏病学会(ESC)心房颤动诊断和管理特别工作组,由ESC欧洲心律协会(EHRA)特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
4
Economic burden of stroke across Europe: A population-based cost analysis.欧洲中风的经济负担:基于人群的成本分析。
Eur Stroke J. 2020 Mar;5(1):17-25. doi: 10.1177/2396987319883160. Epub 2019 Oct 29.
5
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.比较达比加群、利伐沙班和阿哌沙班在房颤中的有效性和安全性:一项全国性队列研究。
Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):75-85. doi: 10.1093/ehjcvp/pvz086.
6
Estimated societal costs of stroke in the UK based on a discrete event simulation.基于离散事件模拟的英国卒中的社会成本估算。
Age Ageing. 2020 Feb 27;49(2):270-276. doi: 10.1093/ageing/afz162.
7
Direct Cost Related to Stroke: A Longitudinal Analysis of Survivors After Discharge From a Rehabilitation Hospital.与中风相关的直接成本:康复医院出院后幸存者的纵向分析。
J Cardiovasc Nurs. 2020 Jan/Feb;35(1):86-94. doi: 10.1097/JCN.0000000000000620.
8
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention.阿哌沙班与依度沙班用于心房颤动患者预防卒中的成本效益分析
Pharmacoecon Open. 2020 Sep;4(3):485-497. doi: 10.1007/s41669-019-00186-7.
9
Feasibility of Atrial Fibrillation Screening With Mobile Health Technologies at Pharmacies.利用移动健康技术在药房进行房颤筛查的可行性
J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):142-151. doi: 10.1177/1074248419879089. Epub 2019 Oct 2.
10
Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.比较达比加群、利伐沙班和阿哌沙班在非瓣膜性心房颤动患者中的安全性和有效性:来自大型医疗保健系统的回顾性研究。
Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):80-90. doi: 10.1093/ehjcvp/pvy044.

中风的成本以及中风时首次诊断心房颤动的发生率。波兰波兹南神经病学病房医院,2018年。

Costs of Stroke and Incidence of First Diagnosis of Atrial Fibrillation at Time of Stroke. Neurology Ward Hospital Poznań, Poland 2018.

作者信息

Zaprutko Tomasz, Florczak-Wyspiańska Jolanta, Kopciuch Dorota, Paczkowska Anna, Ratajczak Piotr, Dorszewska Jolanta, Nowakowska Elżbieta, Kus Krzysztof

机构信息

Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, 7 Rokietnicka St, 60-806 Poznan, Poland.

Department of Neurology, Poznan University of Medical Sciences, 49 Przybyszewskiego St, 60-355 Poznan, Poland.

出版信息

Healthcare (Basel). 2021 Aug 5;9(8):999. doi: 10.3390/healthcare9080999.

DOI:10.3390/healthcare9080999
PMID:34442136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8394020/
Abstract

Stroke is a major cause of morbidity in industrialized countries, representing 8% of total deaths across Europe in 2017. It is also a very costly disorder, frequently caused by atrial fibrillation. We aimed to calculate the cost of stroke hospitalization in 2018 in Poznań (Poland). We also intended to present patients with the first AF diagnosis at the time of stroke. The study was conducted from January 2019 to July 2020. Data were obtained from hospital records and from the hospital accounting department. Out of 164 patients included in the study, 41 had AF and in 18 cases AF was first diagnosed at the time of stroke. The cost of hospitalization in Poznań was EUR 139,257.21 (x¯= EUR 849.13). Among those with concomitant AF, the general cost of inpatient care was EUR 33,859.18 (x¯= EUR 825.83). Considering those who had AF first diagnosed during hospitalization the cost was EUR 16,248.97 (x¯= EUR 906.24). Stroke is associated with high costs of inpatient care, which turned out to be higher among those with AF first diagnosed at the time of stroke. The number of patients who used oral anticoagulants at the time of admission was relatively low. The most frequently used NOAC was dabigatran.

摘要

中风是工业化国家发病的主要原因,在2017年占欧洲总死亡人数的8%。它也是一种成本高昂的疾病,常由心房颤动引起。我们旨在计算2018年波兰波兹南中风住院治疗的费用。我们还打算介绍在中风时首次诊断为房颤的患者。该研究于2019年1月至2020年7月进行。数据来自医院记录和医院会计部门。在纳入研究的164名患者中,41名患有房颤,18例在中风时首次诊断出房颤。波兹南的住院费用为139,257.21欧元(平均值=849.13欧元)。在伴有房颤的患者中,住院护理总费用为33,859.18欧元(平均值=825.83欧元)。对于那些在住院期间首次诊断出房颤的患者,费用为16,248.97欧元(平均值=906.24欧元)。中风与住院护理的高成本相关,事实证明,在中风时首次诊断出房颤的患者中成本更高。入院时使用口服抗凝剂的患者数量相对较少。最常用的非维生素K拮抗剂是达比加群。